替爾泊肽用于2型糖尿病和長期體重管理的快速衛(wèi)生技術(shù)評估

打開文本圖片集

中圖分類號 R977.1+5；R587 文獻標志碼A 文章編號 1001-0408（2025）09-1141-06

DOI 10.6039/j.issn.1001-0408.2025.09.21

ABSTRACTOBJECTIVEToevaluatetheefficacy，safetyandcost-efectivenessof tirzepatidefordiabetes mellitus type （T2DM）andlong-term weight management，and provideevidence-basedbasisforclinicaldrug treatmentand health insurance policy formulation.METHODS Computer searches wereconducted in Embase，PubMed，the Cochrane Library，CNKIand health technologyassssment（HTA）oicialwebsitefromtheirinceptiontoOctober1st224tocollctHTAreport，systematicreview/ meta-analysisandpharmacoeconomicstudyontirzepatideforthetreatmentof T2DMorforweightmanagement.Afterdata extractionandqualityevaluation，descriptiveanalysis was performedontheresearch results.RESULTSTotally18 papers were included，including14systematicreviews/meta-analysesand4 pharmacoeconomics studies，andnoHTAreport wasretrieved.In termsof efficacy，most results showed that the tirzepatide 1 0 m g and were significantly better than other glucagon-like peptide-1（GLP-1） receptor agonists in reducing glycosylated hemoglobin，body weight，and waist circumference（ .In termsof safety，comparedwithoterG-1receptoragonists，tizepatidedidnotincreasetheincidenceofgastrointestialrelated adverse events（AE），the incidence of AE of grade ? 3 ，or the incidence of severe hypoglycemia（ P>0 . 0 5 ）.However，tirzepatide 1 5 m g maysignificantly increased the incidence of hypoglycemia and therateof discontinuation due toadverse reactions（ P < 0.05）.Intermsofcost-effectiveness，basedonthebackgroundofforeignpharmacoeconomicstudies，tirzepatidewasmorecostefectivecomparedtosemaglutideandliraglutideinthetreatmentofT2DMorforweight management.CONCLUSIONS Tirzepatide at dosesof and hasgood efficacy and safety for the treatment of T2DM and for long-term weight management. However，when using the 1 5 m g dose of tirzepatide，close monitoring is required due to the risk of hypoglycemia and discontinuationduetoadversereactions itmaypose.Basedonpharmacoeconomic studiesconductedabroadresults，tirzepatide exhibits economic advantages.

KEYWORDStirzepatide；diabetesmellitus type2；obesity；rapid health technology assessment

世界肥胖聯(lián)盟2024年的研究數(shù)據(jù)顯示：2020年全球約有8.1億成年人患有肥胖癥，預(yù)計到2030年患肥胖癥的人數(shù)將達到12.5億[]。（剩余15713字）